Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GERT: Cetuximab, Radiotherapy, and Temozolomide for Glioblastoma
NCT00311857Phase 2Unknown
- Sponsor
- Heidelberg University
- Start
- Feb 2006
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in glioblastoma multiforme (GBM), sponsored by Heidelberg University. Status: unknown.
02
Drugs
cetuximab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00311857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00311857.